GB Patent

GB2084580A — Aminoalkyl Furan Derivative

Assigned to Glaxo Group Ltd · Expires 1982-04-15 · 44y expired

What this patent protects

A novel crystal form of ranitidine (N-[2-[[[5-(dimethylamino)methyl]-2- furanyl]methyl]thio]ethyl-N'-methyl- 2-nitro-1,1-ethenediamine) hydrochloride, designated Form 2, and having favourable filtration and drying characteristics, is characterised by its infra-red spectrum and x-…

USPTO Abstract

A novel crystal form of ranitidine (N-[2-[[[5-(dimethylamino)methyl]-2- furanyl]methyl]thio]ethyl-N'-methyl- 2-nitro-1,1-ethenediamine) hydrochloride, designated Form 2, and having favourable filtration and drying characteristics, is characterised by its infra-red spectrum and x-ray powder diffraction pattern.

Drugs covered by this patent

Patent Metadata

Patent number
GB2084580A
Jurisdiction
GB
Classification
—
Expires
1982-04-15
Drug substance claim
No
Drug product claim
No
Assignee
Glaxo Group Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.